<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tumors</journal-id><journal-title-group><journal-title xml:lang="ru">Malignant tumours</journal-title><trans-title-group xml:lang="en"><trans-title>Malignant tumours</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2224-5057</issn><issn pub-type="epub">2587-6813</issn><publisher><publisher-name>Rosoncoweb</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18027/2224-5057-2017-3s1-22-25</article-id><article-id custom-type="elpub" pub-id-type="custom">tumors-375</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Облучение лимфатических коллекторов при немелкоклеточном раке легкого: широкое, избирательное или никакого?</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панкратов</surname><given-names>А. Е.</given-names></name></name-alternatives><email xlink:type="simple">pediatrician@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Деньгина</surname><given-names>Н. В.</given-names></name></name-alternatives><email xlink:type="simple">indigo171201@yahoo.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ООО «ПЭТ-Технолоджи Балашиха», Центр онкологии и лучевой терапии, г. Балашиха,</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-2"><institution>ГБУЗ Ульяновский областной онкологический диспансер, г. Ульяновск</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>16</day><month>11</month><year>2017</year></pub-date><volume>0</volume><issue>3s1</issue><fpage>22</fpage><lpage>25</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Панкратов А.Е., Деньгина Н.В., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Панкратов А.Е., Деньгина Н.В.</copyright-holder><copyright-holder xml:lang="en">Панкратов А.Е., Деньгина Н.В.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.malignanttumors.org/jour/article/view/375">https://www.malignanttumors.org/jour/article/view/375</self-uri><abstract><p>В настоящее время существует две основных парадигмы в выборе объема облучения лимфоколлектора при немелкоклеточном раке легкого: 1. Включение в объем облучения только очевидно пораженных тканей легкого и регионарных лимфоузлов, вовлеченных в опухолевый процесс с исключением из полей облучения лимфоузлов с гипотетическим микрораспространением опухолевых клеток. Основная цель в таком выборе – возможность подведения максимальных курабельных доз излучения (более 60 Гр) за счет уменьшения общего объема излучения и снижения лучевой токсичности. 2. Включение в объем облучения как очевидно пораженных лимфоузлов, так и тех, которые теоретически могут иметь очаги микрометастазирования. Основная логика такого выбора заключается в том, что области, требующие подведения высоких доз (более 60 Гр), достаточно малы, а очаги микрометастазирования поддаются дозам облучения не более 50 Гр и, таким образом, может быть увеличена выживаемость. Вопрос, какой же логике следовать при выборе объема облучения лимфоколлекторов, и посвящена данная работа.</p><sec><title> </title><p> </p></sec><sec><title> </title><p> </p></sec></abstract><kwd-group xml:lang="ru"><kwd>немелкоклеточный рак легкого</kwd><kwd>лимфоколлектор</kwd><kwd>лучевая терапия</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998; 352: 257–63.</mixed-citation><mixed-citation xml:lang="en">PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998; 352: 257–63.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small-cell lung cancer. Lang. Сancer. 2005; 47: 81-3.</mixed-citation><mixed-citation xml:lang="en">PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small-cell lung cancer. Lang. Сancer. 2005; 47: 81-3.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Abuodeh YA, Naghavi A. O., DeMarco M, Tonner B, Feygelman V, Stevens CW, Perez BA, Dilling TJ Quantitatively Excessive Normal Tissue Toxicity and Poor Target Coverage in the PORT Meta-Analysis (MA): A Dosimetric Study. Int JRadiat Oncol Biol Phys 2016;96:442.</mixed-citation><mixed-citation xml:lang="en">Abuodeh YA, Naghavi A. O., DeMarco M, Tonner B, Feygelman V, Stevens CW, Perez BA, Dilling TJ Quantitatively Excessive Normal Tissue Toxicity and Poor Target Coverage in the PORT Meta-Analysis (MA): A Dosimetric Study. Int JRadiat Oncol Biol Phys 2016;96:442.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int JRadiat Oncol Biol Phys 2008;72:695–701.</mixed-citation><mixed-citation xml:lang="en">Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int JRadiat Oncol Biol Phys 2008;72:695–701.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Osarogiagbon, R. U., Lin, C. C., Smeltzer, M. P. et al, Prevalence, prognostic implications, and survival modulators of incompletely resected non-small cell lung cancer in the U. S. National Cancer Data Base. J Thorac Oncol. 2016;11: e5 – e16.</mixed-citation><mixed-citation xml:lang="en">Osarogiagbon, R. U., Lin, C. C., Smeltzer, M. P. et al, Prevalence, prognostic implications, and survival modulators of incompletely resected non-small cell lung cancer in the U. S. National Cancer Data Base. J Thorac Oncol. 2016;11: e5 – e16.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lally B. E., Detterbeck F. C., Geiger A. M., Thomas C. R. Jr, Machtay M., Miller A. A. et al. The risk of death from heart disease in patients with non-small cell lung cancer whoreceive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110 (4): 911–7.</mixed-citation><mixed-citation xml:lang="en">Lally B. E., Detterbeck F. C., Geiger A. M., Thomas C. R. Jr, Machtay M., Miller A. A. et al. The risk of death from heart disease in patients with non-small cell lung cancer whoreceive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110 (4): 911–7.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Billiet C., Decaluwй H., Peeters S., Vansteenkiste J., Dooms C., Haustermans K. et al. Modern postoperative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. Radiother. Oncol. 2013; 110 (1): 3–8.</mixed-citation><mixed-citation xml:lang="en">Billiet C., Decaluwй H., Peeters S., Vansteenkiste J., Dooms C., Haustermans K. et al. Modern postoperative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. Radiother. Oncol. 2013; 110 (1): 3–8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Emami B, Graham MV. Lung. In: Perez C, Brady LW, editors. Principles and practice of radiation oncology. New York: Lippincott-Raven; 1998. p. 1181–1220.</mixed-citation><mixed-citation xml:lang="en">Emami B, Graham MV. Lung. In: Perez C, Brady LW, editors. Principles and practice of radiation oncology. New York: Lippincott-Raven; 1998. p. 1181–1220.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenzweig K et al. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2001 Jul 1;50 (3):681–5.</mixed-citation><mixed-citation xml:lang="en">Rosenzweig K et al. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2001 Jul 1;50 (3):681–5.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Van LJ, De Ruysscher D, Wanders R, Boersma L, Simons J, Oellers M, Dingemans AM, Hochstenbag M, Bootsma G, Geraedts W, Pitz C, Teule J, Rhami A, Thimister W, Snoep G, Dehing-Oberije C, Lambin P: Selective nodal irradiation on basis of (18) FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010, 77: 329–336.</mixed-citation><mixed-citation xml:lang="en">Van LJ, De Ruysscher D, Wanders R, Boersma L, Simons J, Oellers M, Dingemans AM, Hochstenbag M, Bootsma G, Geraedts W, Pitz C, Teule J, Rhami A, Thimister W, Snoep G, Dehing-Oberije C, Lambin P: Selective nodal irradiation on basis of (18) FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010, 77: 329–336.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez-Monge R, Fernandes PS, Gupta N, Gahbauer R: Cross-sectional nodal atlas: a tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. Radiology 1999, 211: 815–828.</mixed-citation><mixed-citation xml:lang="en">Martinez-Monge R, Fernandes PS, Gupta N, Gahbauer R: Cross-sectional nodal atlas: a tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. Radiology 1999, 211: 815–828.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718–1723.</mixed-citation><mixed-citation xml:lang="en">Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718–1723.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Giraud P, Antoine M, Larrouy A: Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 48:1015–1024, 2000.</mixed-citation><mixed-citation xml:lang="en">Giraud P, Antoine M, Larrouy A: Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 48:1015–1024, 2000.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Senan S, Chapet O, Lagerwaard FJ, Ten Haken RK: Defining target volumes for non-small cell lung carcinoma. Semin Radiat Oncol 2004, 14: 308–314. 10.1016 / j. semradonc. 2004.07.004.</mixed-citation><mixed-citation xml:lang="en">Senan S, Chapet O, Lagerwaard FJ, Ten Haken RK: Defining target volumes for non-small cell lung carcinoma. Semin Radiat Oncol 2004, 14: 308–314. 10.1016 / j. semradonc. 2004.07.004.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">van Sornsen de Koste JR, Lagerwaard FJ, Nijssen-Visser MRJ: Which margins are necessary for incorporating mediastinal nodal mobility in involved field radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys 53:115–119, 2002.</mixed-citation><mixed-citation xml:lang="en">van Sornsen de Koste JR, Lagerwaard FJ, Nijssen-Visser MRJ: Which margins are necessary for incorporating mediastinal nodal mobility in involved field radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys 53:115–119, 2002.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Giraud P: Influence of CT images visualization parameters for target volume delineation in lung cancer (abstr). Radiother Oncol 56:39, 2000 (suppl 1).</mixed-citation><mixed-citation xml:lang="en">Giraud P: Influence of CT images visualization parameters for target volume delineation in lung cancer (abstr). Radiother Oncol 56:39, 2000 (suppl 1).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">International Commission on Radiation Units and Measurements: Prescribing, Recording, and reporting photon beam therapy. Bethesda, MD: ICRU Report 50, 1993.</mixed-citation><mixed-citation xml:lang="en">International Commission on Radiation Units and Measurements: Prescribing, Recording, and reporting photon beam therapy. Bethesda, MD: ICRU Report 50, 1993.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">International Commission of Radiation Units, Measurements, report no. 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU Report 50). Bethesda, MD: ICRU, 1999.</mixed-citation><mixed-citation xml:lang="en">International Commission of Radiation Units, Measurements, report no. 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU Report 50). Bethesda, MD: ICRU, 1999.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
